<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.117446</article-id><article-id pub-id-type="publisher-id">ACM-43890</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210700000_46691783.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  慢性阻塞性肺疾病氧化应激及对动脉粥样硬化影响的研究进展
  Research Progress of Oxidative Stress in Chronic Obstructive Pulmonary Disease and Its Effect on Atherosclerosis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>发菊</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>华</surname><given-names>毛</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青海大学研究生院，青海 西宁</addr-line></aff><aff id="aff3"><addr-line>青海大学附属医院呼吸内科，青海 西宁</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>07</month><year>2021</year></pub-date><volume>11</volume><issue>07</issue><fpage>3076</fpage><lpage>3082</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  气道氧化应激是影响慢性阻塞性肺疾病(chronic obstructive pulmonary disease, COPD)早期不断发生及持续进展的重要因素。COPD患者可因冷空气刺激、感染等诱因导致病情反复加重，进而引起心衰等心血管疾病(CVD)的发生。动脉粥样硬化是许多CVD发生最早的病理学基本特征，目前它已逐渐发展成为COPD合并CVD临床研究的新热点。氧化应激对动脉粥样硬化的疾病进展具有重要影响。
   Airway oxidative stress is an important factor affecting the continuous occurrence and progression of chronic obstructive pulmonary disease (COPD). Chronic obstructive pulmonary disease (COPD) patients can be repeatedly aggravated due to cold air stimulation, infection and other incentives, and then lead to heart failure and other cardiovascular diseases (CVD). Atherosclerosis is the earliest pathological feature of many CVD, and it has gradually become a new hot spot in the clinical research of COPD combined with CVD. Oxidative stress plays an important role in the progression of atherosclerosis.
 
</p></abstract><kwd-group><kwd>慢性阻塞性肺疾病，氧化应激，动脉粥样硬化, Chronic Obstructive Pulmonary Disease</kwd><kwd> Oxidative Stress</kwd><kwd> Atherosclerosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>气道氧化应激是影响慢性阻塞性肺疾病(chronic obstructive pulmonary disease, COPD)早期不断发生及持续进展的重要因素。COPD患者可因冷空气刺激、感染等诱因导致病情反复加重，进而引起心衰等心血管疾病(CVD)的发生。动脉粥样硬化是许多CVD发生最早的病理学基本特征，目前它已逐渐发展成为COPD合并CVD临床研究的新热点。氧化应激对动脉粥样硬化的疾病进展具有重要影响。</p></sec><sec id="s2"><title>关键词</title><p>慢性阻塞性肺疾病，氧化应激，动脉粥样硬化</p></sec><sec id="s3"><title>Research Progress of Oxidative Stress in Chronic Obstructive Pulmonary Disease and Its Effect on Atherosclerosis<sup> </sup></title><p>Faju Yang<sup>1</sup>, Mao Hua<sup>2</sup></p><p><sup>1</sup>Graduate School of Qinghai University, Xining Qinghai</p><p><sup>2</sup>Department of Respiratory Medicine, Affiliated Hospital of Qinghai University, Xining Qinghai</p><p><img src="//html.hanspub.org/file/27-1572383x4_hanspub.png?20210716082915595" /></p><p>Received: Jun. 12<sup>th</sup>, 2021; accepted: Jul. 1<sup>st</sup>, 2021; published: Jul. 15<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/27-1572383x5_hanspub.png?20210716082915595" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Airway oxidative stress is an important factor affecting the continuous occurrence and progression of chronic obstructive pulmonary disease (COPD). Chronic obstructive pulmonary disease (COPD) patients can be repeatedly aggravated due to cold air stimulation, infection and other incentives, and then lead to heart failure and other cardiovascular diseases (CVD). Atherosclerosis is the earliest pathological feature of many CVD, and it has gradually become a new hot spot in the clinical research of COPD combined with CVD. Oxidative stress plays an important role in the progression of atherosclerosis.</p><p>Keywords:Chronic Obstructive Pulmonary Disease, Oxidative Stress, Atherosclerosis</p><disp-formula id="hanspub.43890-formula12"><graphic xlink:href="//html.hanspub.org/file/27-1572383x6_hanspub.png?20210716082915595"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/27-1572383x7_hanspub.png?20210716082915595" /> <img src="//html.hanspub.org/file/27-1572383x8_hanspub.png?20210716082915595" /></p></sec><sec id="s5"><title>1. 引言</title><p>慢性阻塞性肺疾病(chronic obstructive pulmonary disease, COPD)是一种以不完全可逆性气流受限为特征的疾病，通常由长期暴露于有害颗粒或气体引起。COPD导致肺部病变，但疾病进展也可引起心、脑、肾等肺外器官的病变，CVD是COPD最常见和最重要的合并疾病，对COPD的病死率及预后产生重要影响。相关流行病学随访研究表明，FEV<sub>1</sub>最低的个体心血管死亡风险最高，与最高FEV<sub>1</sub>五分位数的个体相比，风险增加了5倍 [<xref ref-type="bibr" rid="hanspub.43890-ref1">1</xref>]。动脉粥样硬化是很多CVD发病的最早病理表现。有学者 [<xref ref-type="bibr" rid="hanspub.43890-ref2">2</xref>] 提出，氧化应激是COPD和动脉粥样硬化之间的病理生理联系。本文就氧化应激在COPD发病机制中的作用，及其在动脉粥样硬化形成和进展中的影响进行综述。</p></sec><sec id="s6"><title>2. 氧化应激在COPD发病机制中的作用</title><p>近年来对COPD的研究已有了很大进展，但对其发病机制至今尚未完全明了。氧化应激是导致COPD发生和进展的核心机制。在正常状态下，机体内存在抗氧化防御体系，使自由基的产生和消除维持平衡，不会发生氧化损伤，这有利于维持气道的正常功能。当体内氧化物产生量过多时，则会导致机体氧化/抗氧化失衡-氧化应激。氧化物通常是泛指氧的某些代谢产物及含氧衍生物，主要在细胞线粒体内形成。体内的中性粒细胞通过趋化因子和吞噬刺激物激活后，耗氧量增加，葡萄糖磷酸己糖旁路代谢增强，NADPH氧化酶可经甲酰肽、甲酰甲硫酰基–银酰–苯丙氨酸等大量可溶性颗粒性物质诱导活化，引起体内大量的活性氧物质(ROS)产生，如超氧阴离子(O<sup>2−</sup>)、过氧化氢(H<sub>2</sub>O<sub>2</sub>)、次氯酸(HClO)等，这个过程被称为“呼吸爆发”，这些自由基会引起细胞和组织损伤 [<xref ref-type="bibr" rid="hanspub.43890-ref3">3</xref>]。肺内除了氧化物产生系统和酶的激活外，同时有抗氧化防御系统削弱。抗氧化系统的物质主要有超氧化物歧化酶(SOD)及谷胱甘肽(GSH)等。氧化应激的其中一个后果是糖皮质激素抵抗，进而引起许多COPD患者的某些肺外表现，如动脉粥样硬化、肌肉无力和恶病质 [<xref ref-type="bibr" rid="hanspub.43890-ref4">4</xref>]。</p><p>气道中的氧化剂主要包括ROS和活性氮(RNS)。肺组织中产生的ROS/RNS大部分来自中性粒细胞、肺泡巨噬细胞和嗜酸性粒细胞的正常代谢过程，也有支气管、肺泡上皮细胞和内皮细胞因炎症而产生ROS/RNS。线粒体是产生ROS最大的细胞器，通过呼吸链将电子传递给氧形成H<sub>2</sub>O<sub>2</sub>。RNS主要有一氧化氮(NO)、二氧化氮(NO<sub>2</sub>)和过氧化亚硝酸盐(ONOO<sup>−</sup>)。NO由一氧化氮合酶(NOS)催化L-精氨酸生成，当NO浓度较高时，能与氧或过氧化物反应生成活性更强的NO<sub>2</sub>和过氧化氮。当体内的ROS/RNS产生过多时，会引起氧化/亚硝化应激，导致某些细胞成分(磷脂、蛋白质、脂蛋白、核酸和糖)的损害。由此可以推测出，氧化/亚硝化应激可能参与动脉粥样硬化的形成及进展。</p><sec id="s6_1"><title>2.1. 氧化应激与气道上皮损伤</title><p>气道和肺部的ROS/RNS可通过诱导机体中的脂质、蛋白质和DNA等生物大分子发生改变，激活体内的细胞因子和趋化因子，导致炎症细胞活化，直接对气道上皮、纤毛和肺实质等组织造成损伤。细胞因子通过某种信号通路抑制成纤维细胞聚集、增生，降低弹性蛋白合成，导致受损上皮修复延缓甚至不愈，引起相应细胞功能障碍。ROS能与细胞膜磷脂中的多不饱和脂肪酸相互作用，引起其对人体细胞脂质的高度过氧化，使得细胞及其内的细胞器膜氧化受损，从而导致膜的流动性大大减弱，并在一定时间内使细胞发生溶解。此外，脂质过氧化产生的一些醛类产物可促进半胱天冬酶基因表达，导致相应细胞凋亡。相关研究结果表明，氧化剂和抗氧化应激失衡对COPD不同严重程度阶段发挥着重要作用，且氧化应激与该类疾病的严重程度成正比 [<xref ref-type="bibr" rid="hanspub.43890-ref5">5</xref>]。</p></sec><sec id="s6_2"><title>2.2. 氧化应激与蛋白酶/抗蛋白酶失衡</title><p>实验和临床研究都表明α1-抗胰蛋白酶(α1-AT)缺乏症与COPD之间存在关联。α1-AT是一种急性期反应物，在肺防御系统中起关键作用 [<xref ref-type="bibr" rid="hanspub.43890-ref6">6</xref>]。α1-AT的反应中心与中性粒细胞弹性酶的活性位点相匹配，从而形成一个紧密的复合物，然后通过降解从循环中移除。ROS/RNS可以氧化α1-AT活性中心(Met358)的一个关键的蛋氨酸残基，致使其活性降低甚至丧失，引起蛋白酶/抗蛋白酶失衡。另外，RNS增多产生的亚硝化应激可能通过酪氨酸残基的硝化反应造成α1-AT失活。其他抗蛋白酶，如基质金属蛋白酶的组织抑制剂，以及赖氨酸氧化酶(基质蛋白的交联所必需的，如胶原蛋白和弹性蛋白)等酶，也可能受到类似的损伤 [<xref ref-type="bibr" rid="hanspub.43890-ref4">4</xref>]。因此，多种机制作用于降低抗蛋白酶的生物活性，从而损害局部肺抗蛋白酶防御系统，造成肺实质的破坏和肺气肿的形成。</p></sec><sec id="s6_3"><title>2.3. 氧化应激与前炎基因</title><p>氧化应激产生的ROS削弱组蛋白去乙酰化酶的活性，导致染色质结构改变，从而激活前炎基因核因子-κB (NF-κB)、激活蛋白-1，在细胞核内通过与DNA结合，启动其转录过程，上调炎性蛋白基因的表达，促进中性细胞、巨噬细胞在肺内的滞留、活化，从而实现氧化损伤。而炎症细胞的激活又能反过来增加内源性ROS释放、加剧氧化应激。Sarir H等 [<xref ref-type="bibr" rid="hanspub.43890-ref7">7</xref>] 将细胞与抗氧化剂(如N-乙酰半胱氨酸)预孵育，发现可以防止IL-8的过量产生和NF-κB的激活。</p></sec><sec id="s6_4"><title>2.4. 氧化应激与过氧化物氧化还原酶</title><p>尽管关于氧化应激的研究数不胜数，但其对肺产生影响的分子机制仍不明确。过氧化物氧化还原酶(Prdxs)是一类非硒基依赖过氧化物酶超家族，Prdx1~5均含有两个半胱氨酸残基，而Prdx6仅含有一个半胱氨酸残基。Prdx6为一种双重多功能抗氧化蛋白，具有谷胱甘肽过氧化物酶和非钙依赖性磷脂酶A2活性，在肺内抗氧化反应的保护细胞中表达水平较高，并影响肺磷脂代谢。研究发现腺病毒介导的小鼠肺中Prdx6的过表达可以保护小鼠免受高氧的毒性，而Prdx6缺失小鼠对高氧作用更敏感 [<xref ref-type="bibr" rid="hanspub.43890-ref8">8</xref>]。有研究表明，Nrf2的抗氧化作用是通过激活Prdx6的转录表达实现 [<xref ref-type="bibr" rid="hanspub.43890-ref9">9</xref>]。由此可以推测出，Prdx6可能是氧化应激引起COPD发生及进展的分子基础之一。</p></sec></sec><sec id="s7"><title>3. 氧化剂的来源及影响</title><sec id="s7_1"><title>3.1. 吸烟</title><p>吸烟是外源性ROS的主要来源。吸烟引起的经常性氧化应激和持续性炎症可导致广泛的组织损伤和疾病加剧易感性 [<xref ref-type="bibr" rid="hanspub.43890-ref10">10</xref>]。据估计每口香烟烟雾中含有超过10<sup>17</sup>自由基 [<xref ref-type="bibr" rid="hanspub.43890-ref11">11</xref>]。烟雾中被氧化的NO<sub>2</sub>与有机化合物反应，及焦油中的半醌基与O<sub>2</sub>反应产生自由基。由于肺泡表面积庞大及毛细血管丰富，故很容易受到这些自由基的损伤。</p><p>香烟烟雾一旦直接吸入人体肺部很可能直接造成肺部细胞功能受到严重损伤甚或导致细胞死亡，并激活巨噬细胞，诱导中性粒细胞、嗜酸粒细胞、单核细胞在肺部募集和产生活化，活化的炎性细胞通过NADPH氧化酶持续释放大量内源性超氧化物和H<sub>2</sub>O<sub>2</sub>，导致肺部及外周血氧化负荷增加 [<xref ref-type="bibr" rid="hanspub.43890-ref12">12</xref>]。研究发现，吸烟者肺内中性粒及巨噬细胞和氧化物释放较非吸烟者增加，且吸烟者戒烟后活检标本中仍然显示戒烟前相似的炎症反应，提示炎症反应一旦建立可能长期存在。香烟烟雾中的NO能与硫醇反应产生与生物效应相关的亚硝基硫醇，相关研究证实从吸烟者收集的凝结物中亚硝基硫醇水平已被证明高于不吸烟的受试者 [<xref ref-type="bibr" rid="hanspub.43890-ref10">10</xref>]。</p><p>烟草烟雾中的ROS可以导致脂质过氧化和羰基应激，从而导致DNA损伤、变异。观察发现，COPD吸烟者白蛋白羰基化浓度高，提示白蛋白参与清除氧自由基。差向前列腺素是花生四烯酸过氧化的产物，研究表明，COPD患者呼出气冷凝液中差向前列腺素水平升高，与其气道阻塞严重程度密切相关，且与诱导痰中性粒细胞百分比呈正相关 [<xref ref-type="bibr" rid="hanspub.43890-ref13">13</xref>]。暴露于香烟烟雾后，细胞裂解和上皮通透性增加，而GSH可抑制这些作用。香烟烟雾能使抗氧化基因γ谷氨酰半胱氨酸合成酶(γ-GCS)mRNA转录增强，导致呼吸道内衬液(ELF)中GSH含量增多，但此类基因的表达存在明显的个体差异性。</p></sec><sec id="s7_2"><title>3.2. 其他环境</title><p>接触除吸烟以外的环境也会对COPD的病情进展产生重要影响。如生物燃料、工业废气、粉尘、化学物质及其他烟雾同样都会在空气中产生多种氧化物，它们都是发展中国家不吸烟COPD患者高发病率及急性加重的重要因素。大气中可能含有各种各样的粉尘和其他有毒气体，如O<sub>3</sub>、NO<sub>2</sub>、PM和SO<sub>2</sub>。他们本身是具有高度活性的氧化物，通过刺激气道内皮细胞及相应的炎症细胞释放ROS/RNS而增加炎症反应并导致细胞损伤。ROS/RNS会导致肽键的侧链断裂，硝化或氧化损伤相应的蛋白质，也可修饰蛋白质的某个氨基酸侧链 [<xref ref-type="bibr" rid="hanspub.43890-ref14">14</xref>]。来自多个实验室的毒理学研究表明，暴露于O<sub>3</sub>时，气道上皮通透性增加，导致上皮防御屏障破坏，且O<sub>3</sub>能够激活炎症细胞释放有毒介质，损伤细胞和组织 [<xref ref-type="bibr" rid="hanspub.43890-ref15">15</xref>]。</p></sec><sec id="s7_3"><title>3.3. 内源性氧化剂</title><p>大量的吸烟及接触环境污染物时可直接加重肺内的氧化负担，并活化炎性细胞，促使其释放氧化活性物质，即内源性氧化剂。体内白细胞释放自由基；吸入气体中的颗粒物及循环中的细胞因子激活气道内的炎性细胞促发呼吸爆发产生自由基。研究表明，COPD病人氧化应激的发生与血浆中铜离子的增加及锌离子含量下降以及气道和肺泡巨噬细胞中铁离子含量的升高有关。铁离子能够使ELF和肺泡内的自由基浓度上涨，导致细胞膜内的脂质被过氧化，进而引起组织损伤。研究发现，与非吸烟人群相比，COPD患者和非COPD吸烟人群的支气管肺泡灌洗液铁和铁蛋白含量更高 [<xref ref-type="bibr" rid="hanspub.43890-ref16">16</xref>]。</p></sec></sec><sec id="s8"><title>4. 氧化应激对动脉粥样硬化的影响</title><p>许多学者提出COPD不单是一个影响肺部的疾病，还会影响心血管系统，如动脉粥样硬化等。氧化应激可能在由COPD引起的动脉粥样硬化等各种疾病的早期发生发展过程中发挥了重要作用 [<xref ref-type="bibr" rid="hanspub.43890-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.43890-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.43890-ref19">19</xref>]。</p><p>血管中的多种细胞均可产生ROS，如内皮细胞、平滑肌细胞等。此外，血管紧张素II通过血管紧张素II 1型受体(AT1)，激活NADPH氧化酶，产生ROS [<xref ref-type="bibr" rid="hanspub.43890-ref20">20</xref>]。ROS可直接使血管内皮细胞受损，导致内皮依赖性舒张功能障碍，并刺激平滑肌细胞增殖与肥大，从而使血管重构。O<sup>2−</sup>和NO反应生成的ONOO<sup>−</sup>可刺激氧化低密度脂蛋白(OX-LDL)的产生，过多的OX-LDL可使内皮型NO合酶(eNOS)活性降低甚至丧失，从而减少NO生成。另外，四氢生物蝶呤的氧化可能导致eNOS解偶联，减少eNOS衍生的NO，从而增强氧化应激 [<xref ref-type="bibr" rid="hanspub.43890-ref21">21</xref>]。NO活性表达下降时，可通过增强内皮细胞中黏附分子-1 (VCAM-1)及单核细胞趋化蛋白-1 (MCP-1)的表达使其功能增强，加速泡沫细胞的形成。此外，还可激活基质金属蛋白酶(MMP)和基质降解酶的表达，促进了细胞外基质和纤维帽肩部的胶原降解，使纤维帽结构逐渐薄弱，加快斑块破裂，促进动脉粥样硬化进展。</p><p>血管壁内ROS产生系统，包括NADPH氧化酶、黄嘌呤氧化酶、线粒体呼吸链的酶，以及未偶联eNOS [<xref ref-type="bibr" rid="hanspub.43890-ref19">19</xref>]。NADPH氧化酶(NOX)是一种与膜结合酶的复合物，被认为是内皮细胞中ROS的强效刺激因子 [<xref ref-type="bibr" rid="hanspub.43890-ref22">22</xref>]。凝血酶通过刺激P47phox-调控的NADPH氧化酶产生ROS，激活具有JAK/STAT的途径，促进细胞增殖。NOX2，一种特殊的NADPH氧化酶亚型，已被确定为动脉粥样硬化的关键角色 [<xref ref-type="bibr" rid="hanspub.43890-ref23">23</xref>]。罗布麻素是一种化合物，它可以减少NADPH氧化酶亚基p47phox转位到膜亚基NOX2，抑制动物动脉粥样硬化斑块的形成。Quesada等人 [<xref ref-type="bibr" rid="hanspub.43890-ref24">24</xref>] 发现高脂饮食喂养并给予特定NOX2抑制剂的小鼠动脉粥样硬化斑块显著消退。给予大鼠高浓度胆固醇药物饮食后，其血管内皮细胞中NADPH氧化酶、黄嘌呤氧化酶等活性升高，同时血液中的O<sup>2−</sup>也会持续增加，进行SOD抗氧化药物治疗后可以有效减轻甚至完全逆转上述活性变化。</p><p>OX-LDL导致的血管内皮损伤与动脉粥样硬化的早期发病密切相关。血管内皮细胞受损后，血管壁细胞的脂氧合酶及氧自由基可将LDL氧化为OX-LDL。OX-LDL可通过刺激体内的细胞因子，趋化炎性细胞黏附并诱导其进入内皮层，增强血管壁的炎性反应。过氧化物酶体增殖激活受体(PPARs)是核受体超家族的主要成员，PPARγ是PPAR的分子亚型之一，主要调节脂肪细胞分化和改善胰岛素抵抗。有研究表明，PPARγ通过激活CD36受体，使巨噬细胞结合并内化OX-LDL，促进泡沫细胞生成 [<xref ref-type="bibr" rid="hanspub.43890-ref25">25</xref>]。十四烷基硒乙酸(TSA)是一种硒代脂肪酸，被认为具有抗氧化，抗炎和降脂的特性。研究发现，TSA发挥其抗氧化特性是通过延缓人LDL的氧化启动来实现的 [<xref ref-type="bibr" rid="hanspub.43890-ref26">26</xref>]。研究发现，OX-LDL水平与肺功能(FEV<sub>1</sub>%预测)呈负相关，提示OX-LDL可能与气道阻塞的严重程度相关 [<xref ref-type="bibr" rid="hanspub.43890-ref27">27</xref>]。据此，我们可以得出，COPD患者血清OX-LDL水平升高不仅诱发炎症和氧化应激，还可能促进动脉粥样硬化。因此，可以推测出OX-LDL可能是COPD和动脉粥样硬化之间的桥梁。</p></sec><sec id="s9"><title>5. 小结及展望</title><p>目前已有许多研究表明COPD患者CVD发生率呈上升趋势，有学者 [<xref ref-type="bibr" rid="hanspub.43890-ref28">28</xref>] 认为，COPD本身可能是一个独立的心血管危险因素。血管氧化应激导致内皮功能失调，并促进动脉粥样硬化的发生及进展，而氧化应激是COPD的重要发病机制之一，故氧化应激可能在COPD并发CVD的过程中发挥重要作用。未来还需进行一系列实验来研究COPD患者氧化应激引起动脉粥样硬化的相关机制，并研发相关抗氧化药物，旨在降低COPD患者CVD发生率，减轻疾病负担。</p></sec><sec id="s10"><title>文章引用</title><p>杨发菊,华 毛. 慢性阻塞性肺疾病氧化应激及对动脉粥样硬化影响的研究进展Research Progress of Oxidative Stress in Chronic Obstructive Pulmonary Disease and Its Effect on Atherosclerosis[J]. 临床医学进展, 2021, 11(07): 3076-3082. https://doi.org/10.12677/ACM.2021.117446</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43890-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Fuschillo, S., Martucci, M., Donner, C.F. and Balzano, G. (2012) Airway Bacterial Colonization: The Missing Link between COPD and Cardiovascular Events. Respiratory Medicine, 106, 915-923.  
&lt;br&gt;https://doi.org/10.1016/j.rmed.2012.03.023</mixed-citation></ref><ref id="hanspub.43890-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Ghoorah, K., De Soyza, A. and Kunadian, V. (2013) Increased Cardiovascular Risk in Patients with Chronic Obstructive Pulmonary Disease and the Potential Mechanisms Linking the Two Conditions: A Review. Cardiology in Review, 21, 196-202. &lt;br&gt;https://doi.org/10.1097/CRD.0b013e318279e907</mixed-citation></ref><ref id="hanspub.43890-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Hurtado-Nedelec, M., Makni-Maalej, K., Gougerot-Pocidalo, M.A., Dang, P.MC. and El-Benna, J. (2014) Assessment of Priming of the Human Neutrophil Respiratory Burst. In: Quinn, M. and DeLeo, F., Eds., Neutrophil Methods and Protocols, Humana Press, Totowa, Vol. 1124, 405-412. &lt;br&gt;https://doi.org/10.1007/978-1-62703-845-4_23</mixed-citation></ref><ref id="hanspub.43890-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Pandey, R., Singh, M., Singhal, U., Gupta, K.B. and Aggarwal, S.K. (2013) Oxidative/Nitrosative Stress and the Pathobiology of Chronic Obstructive Pulmonary Disease. Journal of Clinical and Diagnostic Research, 7, 580-588. 
&lt;br&gt;https://doi.org/10.7860/JCDR/2013/4360.2832</mixed-citation></ref><ref id="hanspub.43890-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Singh, S., Verma, S.K., Kumar, S., Ahmad, M.K., Nischal, A., Singh, S.K., et al. (2017) Evaluation of Oxidative Stress and Antioxidant Status in Chronic Obstructive Pulmonary Disease. Scandinavian Journal of Immunology, 85, 130-137.  
&lt;br&gt;https://doi.org/10.1111/sji.12498</mixed-citation></ref><ref id="hanspub.43890-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Lakhdar, R., Denden, S., Kassab, A., Leban, N., Knani, J., Lefranc, G., et al. (2011) Update in Chronic Obstructive Pulmonary Disease: Role of Antioxidant and Metabolizing Gene Polymorphisms. Experimental Lung Research, 37, 364-375. &lt;br&gt;https://doi.org/10.3109/01902148.2011.580416</mixed-citation></ref><ref id="hanspub.43890-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Sarir, H., Mortaz, E., Janse, W.T., Givi, M.E., Nijkamp, F.P. and Folkerts, G. (2010) IL-8 Production by Macrophages Is Synergistically Enhanced When Cigarette Smoke Is Combined with TNF-Alpha. Biochemical Pharmacology, 79, 698-705. &lt;br&gt;https://doi.org/10.1016/j.bcp.2009.10.001</mixed-citation></ref><ref id="hanspub.43890-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Manevich, Y. and Fisher, A.B. (2005) Peroxiredoxin 6, a 1-Cys Peroxiredoxin, Functions in Antioxidant Defense and Lung Phospholipid Metabolism. Free Radical Biology and Medicine, 38, 1422-1432.  
&lt;br&gt;https://doi.org/10.1016/j.freeradbiomed.2005.02.011</mixed-citation></ref><ref id="hanspub.43890-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Chowdhury, I., Mo, Y., Gao, L., Kazi, A., Fisher, A.B. and Feinstein, S.I. (2009) Oxidant Stress Stimulates Expression of the Human Peroxiredoxin 6 Gene by a Transcriptional Mechanism Involving an Antioxidant Response Element. Free Radical Biology and Medicine, 46, 146-153. &lt;br&gt;https://doi.org/10.1016/j.freeradbiomed.2008.09.027</mixed-citation></ref><ref id="hanspub.43890-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Fischer, B.M., Voynow, J.A. and Ghio, A.J. (2015) COPD: Balancing Oxidants and Antioxidants. International Journal of Chronic Obstructive Pulmonary Disease, 10, 261-276. &lt;br&gt;https://doi.org/10.2147/COPD.S42414</mixed-citation></ref><ref id="hanspub.43890-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Zinellu, E., Zinellu, A., Fois, A.G., Fois, S.S., Piras, B., Carru, C., et al. (2020) Reliability and Usefulness of Different Biomarkers of Oxidative Stress in Chronic Obstructive Pulmonary Disease. Oxidative Medicine and Cellular Longevity, 2020, Article ID: 4982324. &lt;br&gt;https://doi.org/10.1155/2020/4982324</mixed-citation></ref><ref id="hanspub.43890-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">McGuinness, A.J. and Sapey, E. (2017) Oxidative Stress in COPD: Sources, Markers, and Potential Mechanisms. Journal of Clinical Medicine, 6, Article No. 21. &lt;br&gt;https://doi.org/10.3390/jcm6020021</mixed-citation></ref><ref id="hanspub.43890-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Ko, F.W., Lau, C.Y., Leung, T.F., Wong, G.W.K., Lam, C.W.K. and Hui, D.S.C. (2006) Exhaled Breath Condensate Levels of 8-Isoprostane, Growth Related Oncogene Alpha and Monocyte Chemoattractant Protein-1 in Patients with Chronic Obstructive Pulmonary Disease. Respiratory Medicine, 100, 630-638.  
&lt;br&gt;https://doi.org/10.1016/j.rmed.2005.08.009</mixed-citation></ref><ref id="hanspub.43890-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Tamarit, J., de Hoogh, A., Obis, E., Alsina, D., Cabiscol, E. and Ros, J. (2012) Analysis of Oxidative Stress-Induced Protein Carbonylation Using Fluorescent Hydrazides. Journal of Proteomics, 75, 3778-3788. 
&lt;br&gt;https://doi.org/10.1016/j.jprot.2012.04.046</mixed-citation></ref><ref id="hanspub.43890-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Bhalla, D.K. (1999) Ozone-Induced Lung Inflammation and Mucosal Barrier Disruption: Toxicology, Mechanisms, and Implications. Journal of Toxicology and Environmental Health, Part B, 2, 31-86.  
&lt;br&gt;https://doi.org/10.1080/109374099281232</mixed-citation></ref><ref id="hanspub.43890-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, W.Z., Oromendia, C., Kikkers, S.A., Butler, J.J., O’Beirne, S., Kim, K., et al. (2020) Increased Airway Iron Parameters and Risk for Exacerbation in COPD: An Analysis from SPIROMICS. Scientific Reports, 10, Article No. 10562. &lt;br&gt;https://doi.org/10.1038/s41598-020-67047-w</mixed-citation></ref><ref id="hanspub.43890-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Khosravi, M., Poursaleh, A., Ghasempour, G., Farhad, S. and Najafi, M. (2019) The Effects of Oxidative Stress on the Development of Atherosclerosis. Biological Chemistry, 400, 711-732. &lt;br&gt;https://doi.org/10.1515/hsz-2018-0397</mixed-citation></ref><ref id="hanspub.43890-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Pignatelli, P., Menichelli, D., Pastori, D. and Violi, F. (2018) Oxidative Stress and Cardiovascular Disease: New Insights. Kardiologia Polska, 76, 713-722. &lt;br&gt;https://doi.org/10.5603/KP.a2018.0071</mixed-citation></ref><ref id="hanspub.43890-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Förstermann, U., Xia, N. and Li, H. (2017) Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis. Circulation Research, 120, 713-735. &lt;br&gt;https://doi.org/10.1161/CIRCRESAHA.116.309326</mixed-citation></ref><ref id="hanspub.43890-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Virdis, A., Duranti, E. and Taddei, S. (2011) Oxidative Stress and Vascular Damage in Hypertension: Role of Angiotensin II. International Journal of Hypertension, 2011, Article ID: 916310. &lt;br&gt;https://doi.org/10.4061/2011/916310</mixed-citation></ref><ref id="hanspub.43890-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Li, H., Horke, S. and Förstermann, U. (2014) Vascular Oxidative Stress, Nitric Oxide and Atherosclerosis. Atherosclerosis, 237, 208-219. &lt;br&gt;https://doi.org/10.1016/j.atherosclerosis.2014.09.001</mixed-citation></ref><ref id="hanspub.43890-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Meza, C.A., La Favor, J.D., Kim, D.H. and Hickner, R.C. (2019) Endothelial Dysfunction: Is There a Hyperglycemia-Induced Imbalance of NOX and NOS? International Journal of Molecular Sciences, 20, Article No. 3775.  
&lt;br&gt;https://doi.org/10.3390/ijms20153775</mixed-citation></ref><ref id="hanspub.43890-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Senoner, T. and Dichtl, W. (2019) Oxidative Stress in Cardiovascular Diseases: Still a Therapeutic Target? Nutrients, 11, Article No. 2090. &lt;br&gt;https://doi.org/10.3390/nu11092090</mixed-citation></ref><ref id="hanspub.43890-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Quesada, I.M., Lucero, A., Amaya, C., Meijles, D.N., Cifuentes, M.E., Pagano, P.J., et al. (2015) Selective Inactivation of NADPH Oxidase 2 Causes Regression of Vascularization and the Size and Stability of Atherosclerotic Plaques. Atherosclerosis, 242, 469-475. &lt;br&gt;https://doi.org/10.1016/j.atherosclerosis.2015.08.011</mixed-citation></ref><ref id="hanspub.43890-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Yu, M., Jiang, M., Chen, Y., Zhang, S., Zhang, W., Yang, X., et al. (2016) Inhibition of Macrophage CD36 Expression and Cellular Oxidized Low Density Lipoprotein (oxLDL) Accumulation by Tamoxifen: A Peroxisome Proliferator-Activated Receptor (Ppar)γ-Dependent Mechanism. Journal of Biological Chemistry, 291, 16977-16989.  
&lt;br&gt;https://doi.org/10.1074/jbc.M116.740092</mixed-citation></ref><ref id="hanspub.43890-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Dyrøy, E., Røst, T.H., Pettersen, R.J., Halvorsen, B., Gudbrandsen, O.A., Ueland, T., et al. (2007) Tetradecylselenoacetic Acid, a PPAR Ligand with Antioxidant, Antiinflammatory, and Hypolipidemic Properties. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 628-634. &lt;br&gt;https://doi.org/10.1161/01.ATV.0000255950.70774.d5</mixed-citation></ref><ref id="hanspub.43890-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Shen, Y., Yang, T., Guo, S., Li, X., Chen, L., Wang, T., et al. (2013) Increased Serum ox-LDL Levels Correlated with Lung Function, Inflammation, and Oxidative Stress in COPD. Mediators of Inflammation, 2013, Article ID: 972347. 
&lt;br&gt;https://doi.org/10.1155/2013/972347</mixed-citation></ref><ref id="hanspub.43890-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Ambrosino, P., Lupoli, R., Iervolino, S., De Felice, A., Pappone, N., Storino, A., et al. (2017) Clinical Assessment of Endothelial Function in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review with Meta-Analysis. Internal and Emergency Medicine, 12, 877-885. &lt;br&gt;https://doi.org/10.1007/s11739-017-1690-0</mixed-citation></ref></ref-list></back></article>